| By Aesica Pharma |
| Thursday, 30 July 2009 |
 |
Aesica, a leading supplier of active pharmaceutical ingredients (APIs)
|
|
and finished dosage forms, are pleased to announce a successful completion of its SAP project, which evolved in response to the company’s growing need to support its acquisitions’ programme. The company’s goal was to integrate the SAP system within a very aggressive timeline.
Since its creation through an MBO in 2004, Aesica has grown significantly through acquisitions. The first site was acquired from Merck Sharp & Dohme (MSD) in 2006, located at Ponders End, North London, and is dedicated to API manufacturing.
The second site was acquired from Abbott in 2007 based in Queenborough, Kent, and is specialising in the manufacture of formulations and packaging services.
Speaking at the SAP World Tour 2009 Aesica’s Head of IT, Bhavesh Kotecha said: "Managing information is key when acquiring other sites and companies. We had to ensure we have common policies and processes.”
During the past few years Aesica used a number of ERP systems including a SAP R/3 system, JD Edwards, BPCS and various legacy systems. In 2008 Aesica established its need for a new ERP system and engaged the IBM Express Life Science solution, tailored for the |
|
|
pharmaceuticals industry, with embedded best-practice processes and controls.
Aesica used a standard template from IBM, which provided 85% of the functionality required by the business, leaving 15% customisation work. Kotecha said: "The hardest part of the project was getting the data out. We looked at how to map our data and had a very good internal team to understand the data.”
Aesica successfully completed the data migration and standardised on SAP best-practice processes and applications. This enables Aesica to integrate and understand acquired businesses rapidly, bring efficiencies allowing to maximise shareholders’ value.
The integrated components will allow us to provide consolidated reports from multi-site activities, helping Aesica discover production and process efficiencies. Aesica’s IT are looking further at how to enhance and improve with value added benefits for the business from this “One-Aesica” SAP system.
About Aesica
Aesica is a leading supplier of Active Pharmaceutical Ingredients (APIs), formulated products and custom synthesis solutions to the global pharmaceutical and biotechnology industries. Aesica is a partner of choice to several of the top-ten pharmaceutical companies, leading generic manufacturers and emerging
|
|
life science companies across the major pharmaceutical markets: Europe, North America and Japan.
Aesica has a well-balanced business model and takes a flexible commercial approach working with traditional fee-for-service agreements and also through strategic co-development partnerships with emerging companies. Aesica has three state-of-the-art manufacturing facilities in the UK, which between them spread across more than 200 acres and employ over 700 people.
In September 2008 Aesica established a new US subsidiary, to drive further growth of its business after recent acquisitions of manufacturing sites from Merck Sharpe & Dohme and Abbott, and the move into the manufacture and packaging of finished dosage pharmaceutical products.
For further information:
Aesica Pharmaceuticals Ltd
Maria Koustareva
Marketing Manager
Tel: +44 (0)191 218 1969
marketing@aesica-pharma.com
Want to read more?
Aesica Pharmaceuticals - supplier of APIs, Formulations and Custom Synthesis Solutions
Aesica Acquires Third Major Manufacturing Facility
Aesica establishes US subsidiary to drive further growth in North America |
|
|
